nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.06.2012 | review

Evolving strategies to overcome endocrine resistance in breast cancer

verfasst von: Michael Hubalek, M.D., Christine Brunner, M.D., Christian Marth, M.D.

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Endocrine therapies targeting estrogen action decrease mortality from breast cancer, but their efficacy is limited by intrinsic and acquired therapeutic resistance. Various mechanisms can contribute to insensitivity toward endocrine treatment in hormone receptor-positive breast cancer patients. Definition of the specific genetic lesions and molecular processes that determine clinical endocrine resistance is still incomplete but recently tremendous advances have been made. In this short review the latest strategies to overcome endocrine resistance will be discussed.

Vorheriger Artikel The role of biomarkers in the choice of therapy in breast cancer

Nächster Artikel What’s new in metastatic breast cancer?

Beatson G. On the treatment of inoperable cases of carcinoma of the mammary: suggestions for a new method of treatment with illustrative cases. Lancet. 1896;2(104–107):162–5.CrossRef

Ghayad SE, et al. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2010;126(2):545–62.CrossRefPubMed

Creighton CJ, et al. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008;68(18):7493–501.CrossRefPubMed

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.CrossRef

Forbes JF, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53.CrossRefPubMed

Dowsett M, et al. Growth factor signalling and response to endocrine therapy: the royal marsden experience. Endocr Relat Cancer. 2005;12(Suppl. 1):S113–7.CrossRefPubMed

Gutierrez MC, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005;23(11):2469–76.CrossRefPubMed

Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009;9(8):576–86.CrossRefPubMed

Klinge CM, et al. Estrogen response element sequence impacts the conformation and transcriptional activity of estrogen receptor alpha. Mol Cell Endocrinol. 2001;174(1–2):151–66.CrossRefPubMed

10.

Kushner PJ, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 2000;74(5):311–7.CrossRefPubMed

11.

Smith CL, O’Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev. 2004;25(1):45–71.CrossRefPubMed

12.

Jakacka M, et al. Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J Biol Chem. 2001;276(17):13615–21.PubMed

13.

Gruber CJ, et al. Production and actions of estrogens. N Engl J Med. 2002;346(5):340–52.CrossRefPubMed

14.

Schiff R, et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004;10(1 Pt 2):S331–6.CrossRefPubMed

15.

Lopez-Tarruella S, Schiff R. The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm. Clin Cancer Res. 2007;13(23):6921–5.CrossRefPubMed

16.

Wilson GR, et al. Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer. 2006;95(10):1410–4.CrossRefPubMed

17.

Lombardo LJ, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47(27):6658–61.CrossRefPubMed

18.

Morgan L, et al. Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther. 2009;8(16):1550–8.CrossRefPubMed

19.

De Laurentiis M, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005;11(13):4741–8.CrossRefPubMed

20.

Pietras RJ, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995;10(12):2435–46.PubMed

21.

Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res. 2007;13(7):1950–4.CrossRefPubMed

22.

Osborne CK, et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 2011;17(5):1147–59.CrossRefPubMed

23.

Cristofanilli M, et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res. 2010;16(6):1904–14.CrossRefPubMed

24.

Kaufman B, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529–37.CrossRefPubMed

25.

Johnston S, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538–46.CrossRefPubMed

26.

LoPiccolo J, et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 2008;11(1–2):32–50.CrossRefPubMed

27.

Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol. 2009;10(12):1179–87.CrossRefPubMed

28.

Baselga J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(16):2630–7.CrossRefPubMed

29.

Bachelot TCB, Cropet C, Guastalla J-P, Ferrero J-M, Leger-Falandry C, Soulie P, et al. TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Cancer Res. 2010;70(24):Abst. S1–6.CrossRef

30.

Baselga J, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–9.CrossRefPubMed

31.

Knowlden JM, et al. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance. Breast Cancer Res Treat. 2008;111(1):79–91.CrossRefPubMed

32.

Rosenzweig SA, Atreya HS. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol. 2011;80(8):1115–24.CrossRef

33.

Tolcher AW, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009;27(34):5800–7.CrossRefPubMed

34.

Kaufman PA, Ferrero JM, Bourgeois H, Kennecke H, De Boer R, Jacot W, et al. A randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Cancer Res. 2010;70(76s):S1–4.

35.

Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007;26(37):5310–8.CrossRefPubMed

36.

Huang X, et al. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res. 2009;69(21):8403–11.CrossRefPubMed

37.

Yardley DA, Ismail-Khan R, Klein PM. Entinostat, a novel histone deacetylase inhibitor, added to exemestane improves PFS in advanced breast cancer in a randomized, phase II, double-blind study. Cancer Res. 2011;70(24):PD01–04.

38.

Yue W, et al. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol. 2007;106(1–5):102–10.CrossRefPubMed

39.

Kato K, et al. Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci U S A. 1992;89(14):6403–7.CrossRefPubMed

40.

Johnston SR, et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat. 2008;110(2):327–35.CrossRefPubMed

Titel: Evolving strategies to overcome endocrine resistance in breast cancer
verfasst von: Michael Hubalek, M.D.
Christine Brunner, M.D.
Christian Marth, M.D.
Publikationsdatum: 01.06.2012
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-012-0003-6

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Is distinct EGFR mutation status proof of second simultaneous primary non-small cell lung cancer?

Lung cancer screening: current evidence and recommendations

The role of biomarkers in the choice of therapy in breast cancer

Treatment outcome in AML: a single-centre experience in an unselected patient cohort

Breast cancer—advanced stage: “cure—still a long way to go?”

Highlights in the adjuvant treatment of colon cancer from annual meetings 2011